UroAlert - GU Oncology Daily

July 22, 2026

Videos

Peer-to-Peer Clinical Conversations

Is the Best Yet to Come in Kidney Cancer? - Martin Voss

Martin Voss

Martin Voss discusses three ASCO 2026 kidney cancer oral abstracts.

View

Building a Transformative Career Across Academia, Advocacy, and Biotech - Karen Knudsen

Karen Knudsen discusses her career trajectory and leadership philosophy, tracing her path from PCF-funded prostate cancer researcher to CEO of the Parker Institute for Cancer Immunotherapy.

View

Beyond the Abstracts

Is More Better? Evaluating Neoadjuvant Chemotherapy Cycles Before Surgery for High-Risk Upper Tract Urothelial Carcinoma - Beyond the Abstract

Loss of KDM6A-Mediated Genomic Instability and Metabolic Reprogramming Regulates Response to Therapeutic Perturbations in Bladder Cancer - Beyond the Abstract

Conference Coverage

ASCO 2026: Canadian Cancer Trials Group (CCTG) Study PR21 (PLUDO): Results of Crossover Treatment from a Randomized Trial of 177Lu-PSMA-617 vs Docetaxel in Patients with mCRPC

ASCO 2026: Management in Bladder Cancer after Pathologic Complete Disease Response

AUA 2026: Comparison between IO–IO and IO–TKI Combination Therapies for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

AUA 2026: Machine Learning–based Prediction of Progression to Radical Nephroureterectomy After Endoscopic Management of Upper Tract Urothelial Carcinoma

EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 1: Radiation Toxicity Is Real and Its Urologists Who Manage the Consequences

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Login